Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: A pooled analysis

Wu,Ya‑Lan; Zhou,Lin; Lu,You

doi:10.3892/ol.2016.4783

Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: A pooled analysis

Authors:
- Ya‑Lan Wu
- Lin Zhou
- You Lu
View Affiliations

Affiliations: Department of Oncology, Chengdu Shang Jin Nan Fu Hospital, Chengdu, Sichuan 610041, P.R. China, Department of Thoracic Oncology, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: June 24, 2016 https://doi.org/10.3892/ol.2016.4783
Pages: 1301-1314
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Leptomeningeal metastasis (LM) is increasingly common in patients with non‑small cell lung cancer (NSCLC) due to improved treatment, and ultimately, prolonged patient survival. The current study is a pooled analysis that evaluated intrathecal chemotherapy (ITC) as a treatment for NSCLC patients with LM. The PUBMED, OVID, EBSCO and Cochrane Library databases were searched for published studies involving ITC in NSCLC patients with LM. The primary outcomes of interest included response (symptomatic, radiographic and cytological) and survival. Overall, 4 prospective studies and 5 retrospective studies were included. In total, 37 patients received ITC only, and 552 patients received multiple interventions (ITC, whole‑brain radiotherapy, epidermal growth factor receptor tyrosine kinase inhibitors, systemic chemotherapy and support care). In patients with available individual information, the reevaluated cytological, clinical and radiographic rates of response to ITC were 55% (53‑60%; n=49), 64% (53‑79%; n=58), and 53% (n=32), respectively, and the reevaluated median survival time (from the onset of treatment, n=50) was 6.0 months (95% CI, 5.2‑6.8). In patients without available individual information, the reported cytological and clinical rates of response to ITC are 14‑52% and 13‑50%, respectively, and the reported median survival time (from the diagnosis of LM) was 3.0‑4.3 months. The clinical response rates of patients only receiving ITC varied from 71 to 79% (100% if including stable disease). The median survival time of patients who only received ITC (7.5 months) was much longer than that of patients who received multiple interventions (3.0‑5.0 months). Accordingly, in NSCLC patients with LM, ITC may offer a promising response rate and survival benefits under a suitable regimen. In addition, a suitable combination strategy of multidisciplinary therapy is extremely important for these particular patients.

View Figures

View References

1	Lee SJ, Lee JI, Nam DH, Ahn YC, Han JH, Sun JM, Ahn JS, Park K and Ahn MJ: Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: Impact on survival and correlated prognostic factors. J Thorac Oncol. 8:185–191. 2013. View Article : Google Scholar : PubMed/NCBI
2	Christoph DC and Reckamp KL: Intraventricular chemotherapy for leptomeningeal carcinomatosis from lung cancer: A feasible and beneficial treatment option? J Thorac Oncol. 8:523–524. 2013. View Article : Google Scholar : PubMed/NCBI
3	Nagpal S, Riess J and Wakelee H: Treatment of leptomeningeal spread of NSCLC: A continuing challenge. Curr Treat Options Oncol. 13:491–504. 2012. View Article : Google Scholar : PubMed/NCBI
4	Waki F, Ando M, Takashima A, Yonemori K, Nokihara H, Miyake M, Tateishi U, Tsuta K, Shimada Y, Fujiwara Y and Tamura T: Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol. 93:205–212. 2009. View Article : Google Scholar : PubMed/NCBI
5	Hustu HO, Aur RJ, Verzosa MS, Simone JV and Pinkel D: Prevention of central nervous system leukemia by irradiation. Cancer. 32:585–597. 1973. View Article : Google Scholar : PubMed/NCBI
6	Wasserstrom WR, Glass JP and Posner JB: Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients. Cancer. 49:759–772. 1982. View Article : Google Scholar : PubMed/NCBI
7	Chamberlain MC and Kormanik P: Carcinoma meningitis secondary to non-small cell lung cancer: Combined modality therapy. Arch Neurol. 55:506–512. 1998. View Article : Google Scholar : PubMed/NCBI
8	Liaw CC, Ng KT, Huang JS, Wang CH, Kiu MC and Lai GM: Meningeal carcinomatosis from solid tumors: Clinical analysis of 42 cases. J Formos Med Assoc. 91:299–303. 1992.PubMed/NCBI
9	Taillibert S and Hildebrand J: Treatment of central nervous system metastases: Parenchymal, epidural, and leptomeningeal. Curr Opin Oncol. 18:637–643. 2006. View Article : Google Scholar : PubMed/NCBI
10	Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM and Omuro AM: Leptomeningeal metastasis from non-small cell lung cancer: Survival and the impact of whole brain radiotherapy. J Thorac Oncol. 7:382–385. 2012. View Article : Google Scholar : PubMed/NCBI
11	Yi HG, Kim HJ, Kim YJ, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Kim CS, et al: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer. 65:80–84. 2009. View Article : Google Scholar : PubMed/NCBI
12	Umemura S, Tsubouchi K, Yoshioka H, Hotta K, Takigawa N, Fujiwara K, Horita N, Segawa Y, Hamada N, Takata I, et al: Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama lung cancer study group. Lung Cancer. 77:134–139. 2012. View Article : Google Scholar : PubMed/NCBI
13	Nakamura Y, Takahashi T, Tsuya A, Naito T, Kenmotsu H, Ono A, Shukuya T, Murakami H, Harada H, Watanabe R, et al: Prognostic factors and clinical outcome of patients with lung adenocarcinoma with carcinomatous meningitis. Anticancer Res. 32:1811–1816. 2012.PubMed/NCBI
14	Lee E, Keam B, Kim DW, Kim TM, Lee SH, Chung DH and Heo DS: Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. J Thorac Oncol. 8:1069–1074. 2013. View Article : Google Scholar : PubMed/NCBI
15	Chamberlain MC: Leptomeningeal metastasis. Curr Opin Oncol. 22:627–635. 2010. View Article : Google Scholar : PubMed/NCBI
16	Le Rhun E, Taillibert S and Chamberlain MC: Carcinomatous meningitis: Leptomeningeal metastases in solid tumors. Surg Neurol Int. 4(Suppl 4): S265–S288. 2013.PubMed/NCBI
17	Berg SL and Chamberlain MC: Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis. Curr Oncol Rep. 5:29–40. 2003. View Article : Google Scholar : PubMed/NCBI
18	Martins SJ, Azevedo CR, Chinen LT, Cruz MR, Peterlevitz MA and Gimenes DL: Meningeal carcinomatosis in solid tumors. Arq Neuropsiquiatr. 69:973–980. 2011. View Article : Google Scholar : PubMed/NCBI
19	Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, et al: Central nervous system cancers. J Natl Compr Canc Netw. 9:352–400. 2011.PubMed/NCBI
20	Gwak HS, Lim HS, Shin SH, Yoo H, Han JY, Kim HT, Yun T, Lee JS and Lee SH: Ventriculolumbar perfusion chemotherapy for the treatment of leptomeningeal carcinomatosis: A phase I study with pharmacokinetic data. Am J Clin Oncol. 36:491–499. 2013. View Article : Google Scholar : PubMed/NCBI
21	Nakagawa H, Yamada M, Maeda N, Iwatsuki K, Hirayama A and Ikenaka K: Clinical trial of intrathecal administration of 5-fluoro-2′-deoxyuridine for treatment of meningeal dissemination of malignant tumors. J Neurooncol. 45:175–183. 1999. View Article : Google Scholar : PubMed/NCBI
22	Nakagawa H, Fujita T, Kubo S, Izumoto S, Nakajima Y, Tsuruzono K, Tokiyoshi K and Hayakawa T: Ventriculolumbar perfusion chemotherapy with methotrexate and cytosine arabinoside for meningeal carcinomatosis: A pilot study in 13 patients. Surg Neurol. 45:256–264. 1996. View Article : Google Scholar : PubMed/NCBI
23	Gwak HS, Joo J, Kim S, Yoo H, Shin SH, Han JY, Kim HT, Lee JS and Lee SH: Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol. 8:599–605. 2013. View Article : Google Scholar : PubMed/NCBI
24	Park JH, Kim YJ, Lee JO, Lee KW, Kim JH, Bang SM, Chung JH, Kim JS and Lee JS: Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer. 76:387–392. 2012. View Article : Google Scholar : PubMed/NCBI
25	Hitchins RN, Bell DR, Woods RL and Levi JA: A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol. 5:1655–1662. 1987.PubMed/NCBI
26	Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T and Ettinger DS: Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol. 11:561–569. 1993.PubMed/NCBI
27	Kim DY, Lee KW, Yun T, Park SR, Jung JY, Kim DW, Kim TY, Heo DS, Bang YJ and Kim NK: Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: Methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol. 33:608–612. 2003. View Article : Google Scholar : PubMed/NCBI
28	Kumthekar P, Grimm SA, Avram MJ, Kaklamani V, Helenowski I, Rademaker A, Cianfrocca M, Gradishar W, Patel J, Mulcahy M, et al: Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. J Neurooncol. 112:247–255. 2013. View Article : Google Scholar : PubMed/NCBI
29	Yoshida S and Morii K: Intrathecal chemotherapy for patients with meningeal carcinomatosis. Surg Neurol. 63:52–55; discussion 55. 2005. View Article : Google Scholar : PubMed/NCBI
30	List J, Moser RP, Steuer M, Loudon WG, Blacklock JB and Grimm EA: Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis: Rapid induction of tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, gamma-interferon, and soluble interleukin 2 receptor (Mr 55,000 protein). Cancer Res. 52:1123–1128. 1992.PubMed/NCBI
31	Chen YM, Chen MC, Tsai CM and Perng RP: Intrathecal gemcitabine chemotherapy for non-small cell lung cancer patients with meningeal carcinomatosis-a case report. Lung Cancer. 40:99–101. 2003. View Article : Google Scholar : PubMed/NCBI
32	Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollette S, Schumann GB, Cole BF and Howell SB: A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 5:3394–3402. 1999.PubMed/NCBI
33	Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, et al: A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol. 10:208–215. 2008. View Article : Google Scholar : PubMed/NCBI
34	Jaeckle KA, Batchelor T, O'Day SJ, Phuphanich S, New P, Lesser G, Cohn A, Gilbert M, Aiken R, Heros D, et al: An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol. 57:231–239. 2002. View Article : Google Scholar : PubMed/NCBI
35	Sun JM, Nam MH, Chung JY, Im B, Lee SY, Suh YL, Ahn JS, Park K and Ahn MJ: Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. Cancer Chemother Pharmacol. 68:531–538. 2011. View Article : Google Scholar : PubMed/NCBI
36	Chamberlain MC: A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer. 94:2675–2680. 2002. View Article : Google Scholar : PubMed/NCBI
37	Chamberlain MC, Tsao-Wei DD and Groshen S: Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer. 106:2021–2027. 2006. View Article : Google Scholar : PubMed/NCBI
38	Chamberlain M, Soffietti R, Raizer J, Rudà R, Brandsma D, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Junck L, et al: Leptomeningeal metastasis: A Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro Oncol. 16:1176–1185. 2014. View Article : Google Scholar : PubMed/NCBI
39	Riess JW, Nagpal S, Iv M, Zeineh M, Gubens MA, Ramchandran K, Neal JW and Wakelee HA: Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clin Lung Cancer. 15:202–206. 2014. View Article : Google Scholar : PubMed/NCBI
40	Heimberger AB, Learn CA, Archer GE, McLendon RE, Chewning TA, Tuck FL, Pracyk JB, Friedman AH, Friedman HS, Bigner DD and Sampson JH: Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res. 8:3496–3502. 2002.PubMed/NCBI
41	Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT and Abrey LE: High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer. 103:2344–2348. 2005. View Article : Google Scholar : PubMed/NCBI
42	Palmieri D, Chambers AF, Felding-Habermann B, Huang S and Steeg PS: The biology of metastasis to a sanctuary site. Clin Cancer Res. 13:1656–1662. 2007. View Article : Google Scholar : PubMed/NCBI
43	Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y, Sakamori Y, Nagai H, Kim YH, Katsura T and Mishima M: Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 70:399–405. 2012. View Article : Google Scholar : PubMed/NCBI
44	Chamberlain MC, Junck L, Brandsma D, Soffietti R, Raizer JJ, Ruda R, Boogerd W, Taillibert S, Groves MD, Le Rhun E, et al: Leptomeningeal metastases: A rano proposal for response criteria. J Clin Oncol (suppl). 32:abstr e13019. 2014.